<DOC>
	<DOCNO>NCT00269048</DOCNO>
	<brief_summary>This trial SB-480848 approximately 920 subject Coronary Heart Disease ( CHD ) CHD-risk equivalent examine whether SB-480848 produce sustain inhibition plasma Lp-PLA2 activity , explore effect SB-480848 circulate biomarkers associate cardiovascular risk , evaluate pharmacokinetics , safety tolerability SB-480848 12 week once-daily oral dosing . Subjects first randomize 1:1 double-blind atorvastatin 20 mg 80 mg daily minimum 3 week . Subjects randomize 1:1:1:1 oral dos SB-480848 40 mg , 80 mg , 160 mg placebo daily 12 week . Blood sample collect various timepoints . Vital sign , electrocardiogram , clinical laboratory safety test adverse event assessment perform evaluate safety tolerability SB-480848 .</brief_summary>
	<brief_title>SB-480848 In Subjects With Coronary Heart Disease</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , placebo-controlled , parallel-group , dose-ranging study SB-480848 , oral lipoprotein-associated phospholipase A2 ( Lp-PLA2 ) inhibitor , subject stable coronary heart disease ( CHD ) CHD-risk equivalent examine chronic inhibition Lp-PLA2 , effect circulate biomarkers associate cardiovascular risk , safety tolerability 12 week</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Inclusion criterion : Female subject must nonchildbearing potential . Stable CHD CHDrisk equivalent . Must stable dose statin =4 week LDL &lt; 130 mg/dL ( 3.4 mmol/L ) statin therapy =4 week LDL &lt; 160 mg/dL ( 4.1 mmol/L ) . On stable dose least one oral antiplatelet agent ( e.g. , aspirin , clopidogrel , ticlopidine ) . Exclusion criterion : Recent cardiovascular event / vascular procedure . History difficult manage dyslipidemia . Planned cardiac surgery PCI ( percutaneous coronary intervention ) plan major noncardiac surgery . Inadequately controlled hypertension . Poorly control diabetes mellitus . Serum triglycerides &gt; 400 mg/dL ( 4.52 mmol/L ) . Recent ongoing acute infection . History chronic inflammatory disease . Receiving topical , oral , inhaled injectable corticosteroid . History chronic viral hepatitis , chronic hepatic disorder . History kidney transplant . History myopathy inflammatory muscle disease , elevate total serum CK ( 3 x ULN ) . Severe heart failure ( NYHA class III IV ) , severe leave ventricular dysfunction ( ejection fraction &lt; 30 % ) . Asthma manifest bronchospasm past 6 month , currently take inhale bronchodilator regular basis . History anaphylaxis , anaphylactoid reaction severe allergic response within past 6 month . Malignancy within past 2 year , nonmelanoma skin cancer . Current lifethreatening condition vascular disease may prevent subject complete study . QTc interval &gt; 440 msec ( male ) &gt; 450 msec ( female ) . Alcohol drug abuse within past 6 month . Previous exposure SB480848 . Use investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication ( blind atorvastatin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CHD</keyword>
	<keyword>Lp-PLA2</keyword>
	<keyword>SB-480848</keyword>
</DOC>